1. Atypical lymphocytes in the peripheral blood of COVID-19 patients: A prognostic factor for the clinical course of COVID-19
- Author
-
Takuya Shimmura, Yasunari Miyazaki, Hiroyuki Suzuki, Shinichiro Inoue, Osamu Matsumoto, Masafumi Doi, Sho Shibata, Jun Sugihara, and Ayaka Makino
- Subjects
Male ,Viral Diseases ,Pulmonology ,Physiology ,White Blood Cells ,Medical Conditions ,Animal Cells ,Medicine and Health Sciences ,Lymphocytes ,Respiratory Tract Infections ,Virus Testing ,Multidisciplinary ,medicine.diagnostic_test ,T Cells ,Clinical course ,Middle Aged ,Body Fluids ,Hospitalization ,Chemistry ,Intensive Care Units ,Infectious Diseases ,Blood ,Physical Sciences ,Medicine ,Female ,Cellular Types ,Anatomy ,Research Article ,Chemical Elements ,Adult ,medicine.medical_specialty ,Prognostic factor ,Coronavirus disease 2019 (COVID-19) ,Immune Cells ,Science ,Immunology ,Respiratory Disorders ,Diagnostic Medicine ,Internal medicine ,medicine ,Humans ,Blood test ,Clinical significance ,Blood Cells ,Atypical Lymphocyte ,SARS-CoV-2 ,business.industry ,Biology and Life Sciences ,COVID-19 ,Covid 19 ,Cell Biology ,Pneumonia ,medicine.disease ,Peripheral blood ,Oxygen ,Respiratory Infections ,Leukocytes, Mononuclear ,business ,Leukocyte Disorders - Abstract
Background Clinical observations have shown that there is a relationship between coronavirus disease 2019 (COVID-19) and atypical lymphocytes in the peripheral blood; however, knowledge about the time course of the changes in atypical lymphocytes and the association with the clinical course of COVID-19 is limited. Objective Our purposes were to investigate the dynamics of atypical lymphocytes in COVID-19 patients and to estimate their clinical significance for diagnosis and monitoring disease course. Materials and methods We retrospectively identified 98 inpatients in a general ward at Kashiwa Municipal Hospital from May 1st, 2020, to October 31st, 2020. We extracted data on patient demographics, symptoms, comorbidities, blood test results, radiographic findings, treatment after admission and clinical course. We compared clinical findings between patients with and without atypical lymphocytes, investigated the behavior of atypical lymphocytes throughout the clinical course of COVID-19, and determined the relationships among the development of pneumonia, the use of supplemental oxygen and the presence of atypical lymphocytes. Results Patients with atypical lymphocytes had a significantly higher prevalence of pneumonia (80.4% vs. 42.6%, p < 0.0001) and the use of supplemental oxygen (25.5% vs. 4.3%, p = 0.0042). The median time to the appearance of atypical lymphocytes after disease onset was eight days, and atypical lymphocytes were observed in 16/98 (16.3%) patients at the first visit. Atypical lymphocytes appeared after the confirmation of lung infiltrates in 31/41 (75.6%) patients. Of the 13 oxygen-treated patients with atypical lymphocytes, approximately two-thirds had a stable or improved clinical course after the appearance of atypical lymphocytes. Conclusion Atypical lymphocytes frequently appeared in the peripheral blood of COVID-19 patients one week after disease onset. Patients with atypical lymphocytes were more likely to have pneumonia and to need supplemental oxygen; however, two-thirds of them showed clinical improvement after the appearance of atypical lymphocytes.
- Published
- 2021